Advances in Cancer Immunotherapy for Solid Tumors: Expert Perspectives on The New Data

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: Sep 22, 2016
  • Expires: Sep 22, 2017
  • Average User Rating:
    ( Ratings)

To complete CE activity click here

 

Faculty

 This activity has 4 faculty members associated with it.
Click Here to View All
Julie R.  Brahmer Julie R. Brahmer, MD, MSc
Director, Thoracic Oncology Program
Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview
Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, MD

Robert L.  Ferris Robert L. Ferris, MD, PhD
UPMC Endowed Professor and Chief
Division of Head and Neck Surgery
Associate Director for Translational Research
Co-Leader, Cancer Immunology Program
University of Pittsburgh Cancer Institute
Pittsburgh, PA


Antoni Ribas Antoni Ribas, MD, PhD
Professor of Medicine, Surgery, and Molecular and Medical Pharmacology
University of California, Los Angeles
Director, Tumor Immunology Program
Jonsson Comprehensive Cancer Center
Los Angeles, CA

Target Audience

This activity is intended for clinical oncologists and other healthcare professionals who are involved in selecting immunotherapy regimens and monitoring patients undergoing therapy with immunotherapy agents.

Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the basic principles of tumor immunology and the mechanisms of action of current and emerging cancer immunotherapies used in solid tumors.
  2. Evaluate the latest clinical trial data regarding emerging cancer immunotherapies in head and neck squamous cell carcinoma, non-small cell lung cancer, mesothelioma, gastric cancer, melanoma, and other solid tumors, including use of both monotherapy and combination regimens.
  3. Explore the role of biomarkers in patient selection to improve targeted use of immune checkpoint inhibitors.
  4. Identify practical strategies for using current and emerging cancer immunotherapies, including prevention, early detection, and management of immune-related adverse effects.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

 

PLANNERS:

Joan B. Fowler, PharmD, BCPP, has no relevant financial relationships to disclose in relation to the content of this activity.

Emir Hadzic, PhD, has no relevant financial relationships to disclose in relation to the content of this activity.

 

AUTHORS/PRESENTERS:

Jeffrey S. Weber, MD, PhD (Activity Chair)
Deputy Director, Laura and Isaac Perlmutter Cancer Center, Professor of Medicine, NYU Langone Medical Center, New York, New York

Jeffrey S. Weber, MD, PhD, has disclosed that he consults for and has received less than $10,000 dollars per annum from BMS, Merck, Genentech, AstraZeneca, GSK, Novartis, Nektar Therapeutics, Medivation, Celldex Therapeutics, cCAM, CytomX, Lion Bioscience, Incyte and EMD Serono for membership on advisory boards; holds equity in Celldex, CytomX and cCAM; is not a member of any speakers’ bureau; his institution, but not him personally, received research support from BMS, Merck, GSK, Novartis and AstraZeneca; his laboratory receives research support from Mirati Therapeutics and Acetylon Pharmaceuticals, Inc.

Julie R. Brahmer, MD, MSc
Director, Thoracic Oncology Program; Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview; Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland

Julie R. Brahmer, MD, MSc, has disclosed that she is a consultant for BMS (uncompensated), Celgene, Syndax, Lilly, Merck; receives grant/research support from BMS, Merck, MedImmune/AstraZeneca.

Robert L. Ferris, MD, PhD
University of Pittsburgh Medical Center Endowed Professor and Vice-Chair; Chief, Division of Head and Neck Surgery; Associate Director for Translational Research; Co-Leader, Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Robert L. Ferris, MD, PhD, is a consultant for AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Lilly, and Merck; received grant/research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, VentiRx Pharmaceuticals.

Antoni Ribas, MD, PhD
Professor of Medicine, Surgery, and Molecular and Medical Pharmacology University of California, Los Angeles; Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, Los Angeles, California

Antoni Ribas, MD, PhD, consults for Advaxis, Compugen, CytomX, Five Prime, and FLX Bio; is a major stockholder in Kite Pharma; is not on any scientific advisory boards; is not a member of any speakers’ bureau.

Acknowledgment

Supported by an independent educational grant from AstraZeneca.

Instructions For Participation And Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile